Cobb Stuart 4

What Happened

• Stuart Cobb, Chief Scientific Officer at Neurogene Inc. (NGNE), sold a total of 6,797 shares in three open-market dispositions on March 13, 2026, for aggregate proceeds of approximately $141,446. The individual trades reported were: 3,991 shares at a weighted average price of $20.41 ($81,456), 2,658 shares at $21.34 ($56,722), and 148 shares at $22.08 ($3,268). These were sales (not purchases) and are typically viewed as routine insider liquidity rather than a direct signal about company prospects.

Key Details

• Transaction date: March 13, 2026; Form 4 filed March 17, 2026 (filed 4 days after the trades — check SEC 2-business-day reporting rule for timeliness).
• Prices (weighted averages) and reported ranges:
  • 3,991 shares @ $20.41 (range $19.94–$20.93) — footnote F2
  • 2,658 shares @ $21.34 (range $20.97–$21.96) — footnote F4
  • 148 shares @ $22.08 (range $21.97–$22.16) — footnote F5
• Shares sold total: 6,797; total proceeds: ~$141,446.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes: trades were executed pursuant to a 10b5-1 trading plan adopted Feb 6, 2025 (F1). Footnotes F2–F5 note the reported prices are weighted averages with price ranges and that the filer will provide per-price sale details on request. F3 lists unvested restricted stock units held by the reporting person (details and vesting schedules).

Context

• Because these sales were executed under a pre-established 10b5-1 plan, they were likely automated according to a plan set up earlier and are generally treated as less informative about the insider’s current view of the company. The filing also discloses unvested RSUs (see F3) that remain subject to vesting conditions.